Given the prominent involvement of IL-5 as the primary cytokine responsible for promoting the survival and persistence of eosinophils in the etiology of HES (16), it has been suggested that therapies aimed at inhibiting eosinophils may have the potential to result in favorable therapeutic effects. The gene discussed is IL5; the disease is hypereosinophilic syndrome.